Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 24, 2026, 5:49 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 40 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Ayerza Syndrome Clear all
Terminated No phase listed Observational Accepts healthy volunteers

Measurements and Characterization of Doppler Signals From the Right Chest in Pediatric and Adult Patients

NCT01913457
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
Ultrasound Doppler
Radiation
Lead sponsor
Echosense Ltd.
Industry
Eligibility
Not listed
Enrollment
230 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2021
U.S. locations
2
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Mar 22, 2022 · Synced Jul 24, 2026, 5:49 AM EDT
Withdrawn Phase 4 Interventional

Pulmonary Arterial Hypertension Secondary to Idiopathic Pulmonary Fibrosis and Treatment With Bosentan

NCT00625469
View directory record Official record
Conditions
Pulmonary Arterial Hypertension, Idiopathic Pulmonary Fibrosis
Interventions
bosentan
Drug
Lead sponsor
Rajan Saggar
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
2
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 5, 2018 · Synced Jul 24, 2026, 5:49 AM EDT
Completed Phase 4 Interventional

Characterization of LV Strain Patterns in Mildly Elevated PCWP and PAH.

NCT01800292
View directory record Official record
Conditions
Hypertension, Pulmonary Artery, Ventricular Dysfunction, Left
Interventions
sildenafil
Drug
Lead sponsor
University of Arizona
Other
Eligibility
18 Years to 80 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Nov 3, 2015 · Synced Jul 24, 2026, 5:49 AM EDT
Completed Phase 3 Interventional Results available

Investigation of the Safety and Pharmacology of Dry Powder Inhalation of Treprostinil

NCT03399604
View directory record Official record
Conditions
Primary Pulmonary Hypertension
Interventions
LIQ861 Inhaled Treprostinil
Drug
Lead sponsor
Liquidia Technologies, Inc.
Industry
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
38
States / cities
Phoenix, Arizona • Los Angeles, California • Sacramento, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2024 · Synced Jul 24, 2026, 5:49 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Hormonal, Metabolic, and Signaling Interactions in PAH

NCT01884051
View directory record Official record
Conditions
Idiopathic Pulmonary Arterial Hypertension, Heritable Pulmonary Arterial Hypertension, Scleroderma Associated Pulmonary Arterial Hypertension, Appetite Suppressant Associate PAH
Interventions
Not listed
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
Up to 90 Years
Enrollment
1,899 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2032
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 15, 2025 · Synced Jul 24, 2026, 5:49 AM EDT
Withdrawn Not applicable Interventional

Efficacy Study of Cardizem in Pulmonary Arterial Hypertension

NCT01645826
View directory record Official record
Conditions
Idiopathic Pulmonary Arterial Hypertension, Primary Pulmonary Hypertension, Pulmonary Arterial Hypertension, Familial Primary Pulmonary Hypertension
Interventions
Diltiazem Hydrochloride, Sugar Pill
Drug
Lead sponsor
University of South Florida
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Nov 19, 2018 · Synced Jul 24, 2026, 5:49 AM EDT
Completed No phase listed Observational

Genetic and Environmental Characteristics of Primary Pulmonary Hypertension

NCT00091546
View directory record Official record
Conditions
Lung Diseases, Hypertension, Pulmonary
Interventions
Not listed
Lead sponsor
Vanderbilt University
Other
Eligibility
Up to 100 Years
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 1, 2016 · Synced Jul 24, 2026, 5:49 AM EDT
Completed Phase 1 Interventional Results available

Carnitine Consumption and Augmentation in Pulmonary Arterial Hypertension

NCT04908397
View directory record Official record
Conditions
Pulmonary Arterial Hypertension, Familial Primary Pulmonary Hypertension, Primary Pulmonary Hypertension, Lung Diseases, Carnitine Nutritional Deficiency
Interventions
L-carnitine
Dietary Supplement
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 85 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 29, 2025 · Synced Jul 24, 2026, 5:49 AM EDT
Completed Phase 2 Interventional Results available

GB002 in Adult Subjects With Pulmonary Arterial Hypertension (PAH)

NCT04456998
View directory record Official record
Conditions
Pulmonary Artery Hypertension
Interventions
GB002 (seralutinib), Placebo, Generic Dry Powder Inhaler
Drug · Device
Lead sponsor
GB002, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
36
States / cities
Phoenix, Arizona • Los Angeles, California • Sacramento, California + 31 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2023 · Synced Jul 24, 2026, 5:49 AM EDT
Terminated Not applicable Interventional Results available

Heart Catheterization Using Magnetic Resonance Imaging (MRI) Fluoroscopy and Passive Guidewires

NCT03152773
View directory record Official record
Conditions
Pulmonary Artery Hypertension, Congenital Heart Disease, Structural Heart Disease
Interventions
MRI Heart guidewire catheterization
Diagnostic Test
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 100 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Jul 24, 2026, 5:49 AM EDT
Recruiting No phase listed Observational

Right Ventricle Lipid in Pulmonary Arterial Hypertension (PAH)

NCT05462574
View directory record Official record
Conditions
Idiopathic Pulmonary Arterial Hypertension, Heritable Pulmonary Arterial Hypertension, Pulmonary Arterial Hypertension Associated With Connective Tissue Disease
Interventions
No Intervention
Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Jul 24, 2026, 5:49 AM EDT
Not listed Not applicable Interventional

Right Ventricular Pacing in Pulmonary Arterial Hypertension

NCT04194632
View directory record Official record
Conditions
Pulmonary Artery Hypertension, Right Ventricular Dysfunction
Interventions
Temporary right ventricular pacing
Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 75 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 2, 2021 · Synced Jul 24, 2026, 5:49 AM EDT
Terminated Phase 2 Interventional

PRIMEx - A Study of 2 Doses of Oral CXA-10 in Pulmonary Arterial Hypertension (PAH)

NCT03449524
View directory record Official record
Conditions
PAH
Interventions
75mg CXA-10, 150mg CXA-10, Placebo
Drug · Other
Lead sponsor
Complexa, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
40
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 34 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2020 · Synced Jul 24, 2026, 5:49 AM EDT
Completed Phase 2 Interventional

Trial of Iloprost Inhaled Solution as Add-On Therapy With Bosentan in Subjects With Pulmonary Arterial Hypertension (PAH)

NCT00086463
View directory record Official record
Conditions
Pulmonary Arterial Hypertension, Ayerza Syndrome, Pulmonary Hypertension
Interventions
Iloprost or placebo
Drug
Lead sponsor
Actelion
Industry
Eligibility
12 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
17
States / cities
Birmingham, Alabama • La Jolla, California • Palo Alto, California + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2011 · Synced Jul 24, 2026, 5:49 AM EDT
Completed Not applicable Interventional Results available

A Mobile Health Intervention in Pulmonary Arterial Hypertension

NCT03069716
View directory record Official record
Conditions
Pulmonary Arterial Hypertension, Idiopathic Pulmonary Arterial Hypertension, Heritable Pulmonary Arterial Hypertension, Associated Pulmonary Arterial Hypertension
Interventions
Smartphone Text Messaging, Fitbit Charge HR
Device
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 24, 2021 · Synced Jul 24, 2026, 5:49 AM EDT
Recruiting Not applicable Interventional

Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia (FETO)

NCT03138863
View directory record Official record
Conditions
Congenital Diaphragmatic Hernia, Pulmonary Hypoplasia, Pulmonary Artery Hypertension
Interventions
BALT GoldbBAL2 Detachable Balloon, Catheter System
Device
Lead sponsor
Rodrigo Ruano
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
2
States / cities
Miami, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 22, 2026 · Synced Jul 24, 2026, 5:49 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Observational Study of Actigraphy in Pediatric Pulmonary Arterial Hypertension

NCT04745000
View directory record Official record
Conditions
Hypertension;Pulmonary;Primary
Interventions
Not listed
Lead sponsor
University of Colorado, Denver
Other
Eligibility
Up to 6 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated May 9, 2023 · Synced Jul 24, 2026, 5:49 AM EDT
Recruiting Phase 3 Interventional

EVE TRIAL , ALMA SYSTAM

NCT06646653
View directory record Official record
Conditions
Postpartum Haemorrhage (PPH), PPH, Postpartum Hemorrhage (Primary)
Interventions
Alma System
Device
Lead sponsor
ResQ Medical Ltd
Other
Eligibility
18 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Mar 29, 2026 · Synced Jul 24, 2026, 5:49 AM EDT
Completed No phase listed Observational

Vascular Subphenotypes of Lung Disease in HIV & COPD

NCT01581086
View directory record Official record
Conditions
Pulmonary Artery Hypertension
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 25, 2025 · Synced Jul 24, 2026, 5:49 AM EDT
Completed Phase 3 Interventional

Phase III Randomized Study of UT-15 in Patients With Primary Pulmonary Hypertension

NCT00004497
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
UT-15
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
8 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2000
U.S. locations
7
States / cities
Torrance, California • Chicago, Illinois • Baltimore, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2015 · Synced Jul 24, 2026, 5:49 AM EDT
Terminated Phase 2 Interventional

CXA-10 Study in Subjects With Pulmonary Arterial Hypertension

NCT04053543
View directory record Official record
Conditions
PAH
Interventions
CXA-10
Drug
Lead sponsor
Complexa, Inc.
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
31
States / cities
Birmingham, Alabama • Tucson, Arizona • Anaheim, California + 27 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2020 · Synced Jul 24, 2026, 5:49 AM EDT
Enrolling by invitation Phase 3 Interventional

A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension

NCT03683186
View directory record Official record
Conditions
PAH, Pulmonary Hypertension, Pulmonary Arterial Hypertension, Hypertension, Connective Tissue Diseases, Familial Primary Pulmonary Hypertension, Vascular Diseases, Cardiovascular Diseases, Hypertension, Pulmonary, Lung Diseases, Respiratory Tract Disease
Interventions
Ralinepag
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
48
States / cities
Phoenix, Arizona • Tucson, Arizona • La Jolla, California + 38 more
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced Jul 24, 2026, 5:49 AM EDT
Terminated No phase listed Observational

Reversible Secondary Myelofibrosis or Clonal Myeloproliferative Disorder

NCT00722254
View directory record Official record
Conditions
Primary Myelofibrosis, Primary Pulmonary Hypertension, Secondary Myelofibrosis, Pulmonary Arterial Hypertension
Interventions
Not listed
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
2
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 20, 2016 · Synced Jul 24, 2026, 5:49 AM EDT
Withdrawn No phase listed Observational

Pharmacogenomics in Pulmonary Arterial Hypertension

NCT00593905
View directory record Official record
Conditions
Pulmonary Arterial Hypertension, Pulmonary Hypertension, PAH WHO Group I
Interventions
Sitaxsentan, Bosentan, Ambrisentan
Drug
Lead sponsor
West Penn Allegheny Health System
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 8, 2021 · Synced Jul 24, 2026, 5:49 AM EDT